Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia

DISEASE CHARACTERISTICS: Diagnosis of Waldenstrom's macroglobulinemia confirmed by IgM gammopathy and bone marrow biopsy Presence of lymphoplasmacytic cells CD20+ plasma cell dyscrasia on the majority of malignant cells Bone marrow involvement of 20-50% by core needle biopsy of at least 1.5 cm in length Clinical indication for initiation of treatment, including 1 or more of the following characteristics: Symptoms associated with the disease (e.g., fatigue, asthenia, or painful adenopathy) Anemia IgM greater than 3 g/L Progression as indicated by a rate of IgM rise of more than 0.5 g over 6 months No myelodysplastic syndromes or profound hypocellularity of the bone marrow PATIENT CHARACTERISTICS: Age Over 18 Performance status WHO 0-2 Life expectancy More than 3 months Hematopoietic Absolute neutrophil count greater than 1,500/mm^3 Total B-lymphocyte count less than 5,000/mm^3 Platelet count greater than 100,000/mm^3 No hyperviscosity syndrome Hepatic Bilirubin no greater than 1.5 mg/dL Renal Not specified Other Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 1 year after study completion No uncontrolled CNS disease No serious nonmalignant disease that would preclude study participation No other concurrent active malignancy except controlled skin cancer or prostate cancer PRIOR CONCURRENT THERAPY: Biologic therapy More than 2 weeks since prior filgrastim (G-CSF) or sargramostim (GM-CSF) More than 4 months since prior rituximab No prior radioimmunotherapy Chemotherapy No prior high-dose chemotherapy (unless patient has had prior back-up stem cell collections) More than 6 weeks since prior chemotherapy Endocrine therapy More than 4 weeks since prior corticosteroids Radiotherapy No prior radiotherapy Surgery Not specified